Imidlertid kan en samlet 24 ugers behandlingsperiode være forbundet med større risiko for tilbagefald end en 48 ugers behandlingsperiode (se afsnit 5. 1). • Genotype 2 eller 3:
However, an overall 24 weeks treatment duration may be associated with a higher risk of relapse than a 48 weeks treatment duration (see section 5.1). • Genotypes 2 or 3: